Brief Communication: PDF OnlyAdverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel DiseaseBotwin, Gregory J.1,4; Li, Dalin PhD1,4; Figueiredo, Jane PhD2; Cheng, Susan MD, MMSc, MPH3; Braun, Jonathan MD, PhD1,4,5; McGovern, Dermot P.B. MD, PhD1,4,5; Melmed, Gil Y. MD, MS1,4Author Information 1Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases 2Cedars-Sinai Cancer 3Departmet of Cardiology, Smidt Heart Institute, Cedars-Sinai, Los Angeles, CA 90048 4Department of Medicine, Cedars-Sinai, Los Angeles, CA 90048 5Department of Biomedical Sciences, Cedars-Sinai, Los Angeles, CA 90048 Corresponding Author: Gil Y. Melmed, MD, MS, FACG, AGAF, Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, 310-423-4100, [email protected] Received April 02, 2021 Accepted May 18, 2021 The American Journal of Gastroenterology: May 25, 2021 - Volume Latest Articles - Issue - doi: 10.14309/ajg.0000000000001342 Buy PAP Metrics Abstract Patients with immune-mediated inflammatory diseases (IMID) such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from SARS-CoV-2 mRNA vaccine trials. We thus evaluated post-mRNA vaccination adverse events (AE) in 246 vaccinated adults with IBD participating in a longitudinal vaccine registry. In general, AE frequency was similar to that reported in the general population. AE were more common among younger patients, and those with prior COVID-19. We additionally found that AE were less common in individuals receiving biologic therapy. Those with IBD and other IMID on these commonly prescribed therapies can be reassured that the AE risk is likely not increased, and may be reduced, while on biologics. © The American College of Gastroenterology 2021. All Rights Reserved.